How to Stack SS-31 + MOTS-C (Exact Dosing Protocol)
Your mitochondria are doing two different jobs at the same time, and most people trying to optimize them are only addressing one.
To understand why stacking SS-31 and MOTS-c makes sense, you need the full picture of what mitochondria actually do and where they break down.
Mitochondria produce energy through a chain of protein complexes embedded in the inner membrane, something called the electron transport chain, which is essentially a series of pumps that move hydrogen ions across the inner membrane to generate ATP. That process requires the membrane itself to stay tightly folded and structurally intact, and it generates free radicals as a byproduct, which over time damage the membrane further and create a self-reinforcing cycle of decline.
That is the structural problem. But there is a separate problem layered on top of it.
As the cell senses that mitochondrial output is falling, it starts making regulatory decisions, scaling back the production of new mitochondria, reducing the activity of metabolic pathways, and gradually allowing the network to shrink. This is not just structural damage. It is a signaling problem, where the cell has essentially adjusted its expectations downward.
SS-31 addresses the first problem. MOTS-c addresses the second. That is the reason the combination is worth understanding.
SS-31 works by binding to something called cardiolipin, which is a specialized fat molecule found almost exclusively in the inner mitochondrial membrane and which acts as a structural anchor for the protein complexes that produce energy. When cardiolipin oxidizes and becomes damaged, those complexes lose their geometry, electron transfer becomes inefficient, and more free radicals leak out and damage more cardiolipin in a loop. SS-31 binds directly to cardiolipin, stabilizes it, and pulls the electron transport chain complexes back into alignment.
Because it binds a lipid and not a receptor, there is no desensitization mechanism. There is nothing to downregulate. A 168-week continuous trial in patients with Barth syndrome, a rare mitochondrial cardiomyopathy, showed progressive improvement with no tolerance over that period. That is over three years of daily dosing with continued benefit.
The dosing data is also clarifying here. A phase 2/3 clinical trial comparing 4 milligrams to 40 milligrams found no advantage at the higher dose. This matters because SS-31 concentrates approximately 5,000-fold at the inner mitochondrial membrane, meaning the molecule is extraordinarily efficient at reaching its target even at low doses. The practical range for most applications is 1 to 5 milligrams daily, and the molecule needs to be run consistently because the structural repair it enables accumulates over weeks, not hours.
MOTS-c works through an entirely different mechanism.
MOTS-c is something your mitochondria already produce. It is what is called a mitochondrial-derived peptide, which means it is a signaling molecule encoded in mitochondrial DNA, not nuclear DNA, and it circulates to affect cellular behavior in the muscle, liver, and other metabolic tissues. Its half-life is short. But the work it does is not through plasma levels. It works through gene expression.
Specifically, MOTS-c activates something called AMPK, which is a cellular energy sensor that functions like a fuel gauge and which, when activated, triggers a cascade of downstream effects including increased mitochondrial biogenesis, improved glucose uptake, and a reduction in oxidative stress. The cascade keeps running well after the peptide has cleared.
A 2021 Nature Communications study demonstrated that after a loading period of daily dosing, dropping to three times per week maintained all the benefits that had been established. This is the mechanism that justifies the lower dosing frequency. You are not maintaining plasma levels. You are maintaining the gene expression state those levels induced.
A more recent study published in Free Radical Biology and Medicine found that MOTS-c improves mitochondrial quality and efficiency through a PGC-1alpha and AMPK-dependent pathway without simply increasing mitochondrial quantity. The distinction matters because you can have more mitochondria that are still dysfunctional. MOTS-c appears to improve what the existing network can actually do.
Because MOTS-c is endogenous, there is no known feedback loop of the kind you see with exogenous testosterone, where supplementation suppresses the body's own production. In animal studies, it was administered continuously for the full lifespan of the subjects with sustained benefits throughout.
So the combination looks like this. SS-31 runs daily at 1 to 5 milligrams because its structural repair requires consistent exposure and accumulates over time. MOTS-c runs three times per week at a total of 5 to 15 milligrams because its downstream signaling outlasts the peptide itself and does not require daily presence to remain active. A common starting point in clinical practice is 2 milligrams SS-31 daily and 10 milligrams MOTS-c per week, roughly 3 to 4 milligrams per injection on Monday, Wednesday, and Friday.
The cycling question deserves a direct answer. The standard recommendation of 8 to 12 weeks on and 4 to 8 weeks off is not based on evidence that either compound requires it. SS-31 has no receptor to desensitize and the longest continuous human trial ran it for 168 weeks. MOTS-c has no suppression mechanism. The cycling guidance is precautionary, reflecting the absence of long-term human data at these specific doses rather than any known biological reason to stop.
One thing to name clearly: no published human study has tested these two compounds in combination. The rationale for stacking them is built on mechanism, specifically that they act on different parts of the same problem without redundancy or interaction. The closest published analog is a 2020 study showing synergy between SS-31 and NMN in aged mice, which supports the general logic of combining structural repair with metabolic signaling but is not direct evidence for this particular combination.
The deeper point here is about the level at which these compounds operate.
Most interventions work by adding more of something, more fuel, more growth signal, more stimulation. What both of these do is different. They work at the level of cellular infrastructure, one stabilizing the physical machinery and the other updating the software the cell uses to run it.
When that infrastructure is compromised, adding more fuel to a damaged system does not fix it. You have to address the system first. That is what this protocol is actually trying to do.
References
- Thompson WR, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a mitochondrial cardiomyopathy. Genetics in Medicine. 2024;267:101133. 168-week continuous SS-31 at 40mg daily with progressive improvement and no tolerance. Source
- Butler J, et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF phase 2 trial. Journal of Cardiac Failure. 2020;265:429-437. 4mg vs 40mg comparison: 40mg showed no advantage over 4mg. Source
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. 3x/week maintenance dosing preserved all benefits after daily loading. Source
- Gudiksen A, et al. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1alpha/AMPK-dependent manner. Free Radical Biology and Medicine. 2026;246:682-696. MOTS-C improves mitochondrial quality without increasing content, reduces ROS. Source
- Whitson JA, et al. SS-31 and NMN: Two paths to improve metabolism and function in aged hearts. Aging Cell. 2020;1910:e13213. Closest published combination data: SS-31 + NMN synergy in aged mice. Source
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;213:443-454. Original MOTS-C dosing data: 0.5mg/kg chronic, 5mg/kg acute in mice. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.